Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain

被引:95
|
作者
Higashi, Shinji
Moore, Darren J.
Colebrooke, Rebecca E.
Biskup, Saskia
Dawson, Valina L.
Arai, Heii
Dawson, Ted M.
Emson, Piers C. [1 ]
机构
[1] Babraham Inst, Lab Mol Neurosci, Cambridge, England
[2] Juntendo Univ, Sch Med, Dept Psychiat, Tokyo 113, Japan
[3] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD USA
[4] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD USA
[5] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD USA
[6] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD USA
关键词
dardarin; immunohistochemistry; in situ hybridization; PARK8; parkinsonism; Parkinson's disease;
D O I
10.1111/j.1471-4159.2006.04246.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) have been identified as the cause of familial Parkinson's disease (PD) at the PARK8 locus. To begin to understand the physiological role of LRRK2 and its involvement in PD, we have investigated the distribution of LRRK2 mRNA and protein in the adult mouse brain. In situ hybridization studies indicate sites of mRNA expression throughout the mouse brain, with highest levels of expression detected in forebrain regions, including the cerebral cortex and striatum, intermediate levels observed in the hippocampus and cerebellum, and low levels in the thalamus, hypothalamus and substantia nigra. Immunohistochemical studies demonstrate localization of LRRK2 protein to neurones in the cerebral cortex and striatum, and to a variety of interneuronal subtypes in these regions. Furthermore, expression of LRRK2 mRNA in the striatum of VMAT2-deficient mice is unaltered relative to wild-type littermate controls despite extensive dopamine depletion in this mouse model of parkinsonism. Collectively, our results demonstrate that LRRK2 is present in anatomical brain regions of direct relevance to the pathogenesis of PD, including the nigrostriatal dopaminergic pathway, in addition to other regions unrelated to PD pathology, and is likely to play an important role in the normal function of telencephalic forebrain neurones and other neuronal populations.
引用
收藏
页码:368 / 381
页数:14
相关论文
共 50 条
  • [21] The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
    Mark R. Cookson
    Nature Reviews Neuroscience, 2010, 11 : 791 - 797
  • [22] The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
    Cookson, Mark R.
    NATURE REVIEWS NEUROSCIENCE, 2010, 11 (12) : 791 - 797
  • [23] Heart rate variability biomarkers of leucine-rich repeat kinase 2-associated Parkinson's disease
    Naranjo, Claudia Carricarte
    Marras, Connie
    Visanji, Naomi P.
    Cornforth, David J.
    Sanchez-Rodriguez, Lazaro
    Schuele, Birgitt
    Goldman, Samuel M.
    Estevez, Mario
    Stein, Phyllis K.
    Lang, Anthony E.
    Machado, Andres
    Jelinek, Herbert F.
    2020 11TH CONFERENCE OF THE EUROPEAN STUDY GROUP ON CARDIOVASCULAR OSCILLATIONS (ESGCO): COMPUTATION AND MODELLING IN PHYSIOLOGY NEW CHALLENGES AND OPPORTUNITIES, 2020,
  • [24] Effects of sevoflurane on leucine-rich repeat kinase 2-associated Drosophila model of Parkinson's disease
    Shan, Zhiming
    Cai, Song
    Zhang, Tao
    Kuang, Liting
    Wang, Qi
    Xiu, Huanhuan
    Wen, Jing
    Gu, Huaiyu
    Xu, Kangqing
    MOLECULAR MEDICINE REPORTS, 2015, 11 (03) : 2062 - 2070
  • [25] 18F-Labelled pyrrolopyrimidines reveal brain leucine-rich repeat kinase 2 expression implicated in Parkinson's disease
    Chen, Xueyuan
    Zhang, Qiuyang
    Zhang, Yunming
    Fang, Jianyang
    Jiang, Donglang
    Mou, Zhaobiao
    Liu, Huanhuan
    Su, Rong
    Wang, Chao
    He, Fengming
    Chen, Xiaochun
    Xie, Fang
    Pan, Xiaodong
    Li, Zijing
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 214
  • [26] A new approach to Parkinson's disease: inhibition of leucine-rich repeat kinase-2
    Doggrell, Sheila A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (04) : 587 - 590
  • [27] Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2
    Tong, Youren
    Shen, Jie
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 1042 - 1046
  • [28] Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease
    Domingos, Sofia
    Duarte, Teresa
    Saraiva, Lucilia
    Guedes, Rita C.
    Moreira, Rui
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (15) : 1953 - 1977
  • [29] A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease
    Melrose, H. L.
    Kent, C. B.
    Taylor, J. P.
    Dachsel, J. C.
    Hinkle, K. M.
    Lincoln, S. J.
    Mok, S. S.
    Culvenor, J. G.
    Masters, C. L.
    Tyndall, G. M.
    Bass, D. I.
    Ahmed, Z.
    Andorfer, C. A.
    Ross, O. A.
    Wszolek, Z. K.
    Delldonne, A.
    Dickson, D. W.
    Farrer, M. J.
    NEUROSCIENCE, 2007, 147 (04) : 1047 - 1058
  • [30] Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease
    Carricarte Naranjo, Claudia
    Marras, Connie
    Visanji, Naomi P.
    Cornforth, David J.
    Sanchez-Rodriguez, Lazaro
    Schule, Birgitt
    Goldman, Samuel M.
    Estevez, Mario
    Stein, Phyllis K.
    Lang, Anthony E.
    Jelinek, Herbert F.
    Machado, Andres
    CLINICAL AUTONOMIC RESEARCH, 2019, 29 (06) : 603 - 614